An italian multicenter study for application of a diagnostic algorithm in autoantibody testing

Area of Science:

• Clinical immunology
• Rheumatology
• Laboratory medicine

Background:

• Autoimmune rheumatic diseases are diagnosed using autoantibody tests like antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), and antiextractable nuclear antigens (anti-ENA).
• Requests for these diagnostic tests have increased significantly in recent years.
• A guideline implemented in Parma Hospital in 2007 successfully reduced inappropriate autoantibody testing.

Purpose of the Study:

• To evaluate the applicability of autoantibody testing guidelines in a broader geographical area (Parma, Modena, Piacenza, Reggio-Emilia).
• To improve the efficiency and clinical effectiveness of diagnosing and monitoring autoimmune rheumatic diseases.
• To assess the impact of common guidelines on reducing second-level autoantibody test requests.

Main Methods:

• A study group of clinicians and laboratory physicians evaluated diagnostic criteria and testing procedures.
• Common guidelines for autoantibody testing were developed, considering clinical needs.
• Compliance with the guidelines was assessed in participating hospitals.

Main Results:

• The Parma Hospital guideline led to a significant reduction in anti-dsDNA (23.9%) and anti-ENA (20.7%) test requests.
• The study aimed to replicate and assess these reductions in a wider region.
• The project involved evaluating diagnostic criteria, analytical procedures, and test volumes.

Conclusions:

• Validating common guidelines for laboratory diagnosis of autoimmune rheumatic diseases is crucial.
• These guidelines can improve patient outcomes and economic efficiency in healthcare.
• Standardized autoantibody testing protocols enhance diagnostic accuracy and resource allocation.